Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2270

Sort by

Sort Order Select

Journal Articles

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

Blood (2021) 137 (19): 2681–2693.

https://doi.org/10.1182/blood.2019004571

Published: 2021

Includes: Supplemental data

Journal Articles

Thrombopoietin Has Protective Effect in Neonatal Hypoxia-Ischemia Rat Model

Liang Li, PhD, Liuming Yang, Hongwu Xin, Beng H Chong, MBBS, PhD, Mo Yang, MD

Blood (2019) 134 (Supplement_1): 4898.

https://doi.org/10.1182/blood-2019-131575

Published: 2019

Journal Articles

Sickle Cell Hemoglobin Impairs Lysosomal Processing in Macrophages Leading to Inflammasome Activation and Inflammation

Marina Jerebtsova, PhD, Xiaomei Niu, MD, Sharmin Diaz, NP, Namita Kumari, PhD, Sergei Nekhai, PhD

Blood (2019) 134 (Supplement_1): 979.

https://doi.org/10.1182/blood-2019-130741

Published: 2019

Journal Articles

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Lakshmi Reddy Palam, PhD, Baskar Ramdas, PhD, Katelyn Pickerell, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 723.

https://doi.org/10.1182/blood-2019-131036

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Caitlin W Elgarten, MD MSc, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Richard Aplenc, MD PhD, Michael T. Hemmer, MS, Mukta Arora, MD, Stephen R. Spellman, MS, Tao Wang, PhD, Madan Jagasia, MBBS, MS, MMHC, Margaret L. MacMillan, MD, Joseph Pidala, MD, Brian T. Fisher, DO, MSCE, Matt Hall, PhD

Blood (2019) 134 (Supplement_1): 599.

https://doi.org/10.1182/blood-2019-130466

Published: 2019

Journal Articles

Phase-I Study of ETA Receptor Antagonist Ambrisentan in Sickle Cell Disease

Abdullah Kutlar, MD, Jennifer Pollock, PhD, Steffen E. Meiler, MD, Ryan Harris, PhD CEP, FACSM, Xu Hongyan, PhD, Leigh Wells, MSN, Latanya Bowman, RN, Sharon Jones, BS, David M. Pollock, PhD

Blood (2019) 134 (Supplement_1): 617.

https://doi.org/10.1182/blood-2019-130036

Published: 2019

Journal Articles

Platelet CD34 Expression and a Congenital Collar Bone Malformation Associated with a Partial CBFB Deletion in a Case with a Bleeding Disorder

Maaike G.J.M. van Bergen, MSc, Joline L. Saes, MD, Annet Simons, PhD, Konnie M. Hebeda, PhD, Yvonne M.C. Henskens, PhD, Britta A.P. Laros-vanGorkom, MD PhD, Saskia E.M. Schols, MD PhD, Frank W.M.B. Preijers, PhD, Marjolijn C. Jongmans, MD PhD, Joop H. Jansen, PhD, Bert A. Van der Reijden, PhD

Blood (2019) 134 (Supplement_1): 1077.

https://doi.org/10.1182/blood-2019-128414

Published: 2019

Journal Articles

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Blood (2019) 134 (Supplement_1): 2472.

https://doi.org/10.1182/blood-2019-129056

Published: 2019

Journal Articles

Rspo-LGR4 Cooperates with HOXA9 to Sustain Self-Renewal in Acute Myeloid Leukemia

Nunki Hassan, Basit Salik, Alastair Duly, PhD, Jenny Yingzi Wang, PhD

Blood (2019) 134 (Supplement_1): 2669.

https://doi.org/10.1182/blood-2019-129704

Published: 2019

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

Growth Factor-Dependent Activation of a MYC-Induced Latent AML Program in Human Hematopoietic Cells

Elizabeth Bulaeva, Davide Pellacani, PhD, Naoto Nakamichi, MD PhD, Philip Beer, MD PhD, Colin Hammond, Alireza Lorzadeh, Michelle Moksa, Annaick Carles, Misha Bilenky, Sylvain Lefort, PhD, Jeremy Shu, Brian T. Wilhelm, PhDBSc, Andrew P. Weng, MD PhD, Martin Hirst, PhD, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 2533.

https://doi.org/10.1182/blood-2019-122768

Published: 2019

Journal Articles

Single Cell Signaling Responses Stratify Immune and Leukemia Cell Populations in Acute Myeloid Leukemia

Kathryn I Sunthankar, MD, Benjamin J Reisman, BS, Candace H Cote, BS, Paul Brent Ferrell, Jr., MD

Blood (2019) 134 (Supplement_1): 2680.

https://doi.org/10.1182/blood-2019-129602

Published: 2019

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 5552.

https://doi.org/10.1182/blood-2019-123672

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

Thrombopoietin Has Protective Effect in Neonatal Hypoxia-Ischemia Rat Model

Sickle Cell Hemoglobin Impairs Lysosomal Processing in Macrophages Leading to Inflammasome Activation and Inflammation

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)

Phase-I Study of ETA Receptor Antagonist Ambrisentan in Sickle Cell Disease

Platelet CD34 Expression and a Congenital Collar Bone Malformation Associated with a Partial CBFB Deletion in a Case with a Bleeding Disorder

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Rspo-LGR4 Cooperates with HOXA9 to Sustain Self-Renewal in Acute Myeloid Leukemia

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Growth Factor-Dependent Activation of a MYC-Induced Latent AML Program in Human Hematopoietic Cells

Single Cell Signaling Responses Stratify Immune and Leukemia Cell Populations in Acute Myeloid Leukemia

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only